Finally, the SIOP-Europe high-risk medulloblastoma trial is using molecular screening to identify appropriate cases for increased-intensity treatments, including MYC/MYCN amplification (excluding MYCN amplified Group 4 MB) and SHH-alpha MB (EudraCT Number: 2018-004250-17). This evidence concerns the gene MYCN and medulloblastoma.